Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 EP858 | DOI: 10.1530/endoabs.90.EP858

ECE2023 Eposter Presentations Pituitary and Neuroendocrinology (234 abstracts)

Dual Endocrinopathy – a Case Vignette

Wenhui Huang

Tan Tock Seng Hospital, General Medicine, Singapore, Singapore

Initial Presentation (February 2018) A 54 years old Chinese male attended the Emergency Department of a public hospital in February 2018 for psychotic symptoms of 1-month duration. He has a past medical history of bifrontal craniotomy 20 years ago for brain tumour. A computed tomography scan of the head was performed which showed increased pituitary fossa and suprasellar space soft tissue. A pituitary hormone panel was performed [Table 1]. He was diagnosed with Grave’s disease and started on oral Carbimazole 5mg OM and given an Endocrinology outpatient appointment. Subsequent Follow Up (June 2018) He was seen in an Endocrinology outpatient clinic in June 2018 with the following blood test result [Table 2]. His Carbimazole was reduced from 5mg OM to 2.5mg OM. Another Emergency Department Attendance (October 2018) He attended the Emergency Department of another hospital in Oct 2018 for headache & giddiness. A thyroid panel was performed [Table 2]. Evolving central hypothyroidoism with panhypopituitarism was suspected. A short synacthen test and a repeat pituitary panel confirmed this. Magnetic resonance imaging of the brain subsequently confirmed the presence of a pituitary macroadenoma.

Table 1
Hormonal TestReference RangeResults [Feb 2018]
8am Cortisol
Adrenocorticotrophic Hormone (ACTH)1.6-13.9pmol/l404
Random Growth Hormone (GH)<3.0 mg/l0.07
Insulin-like Growth Factor 1 (IGF-1)48-209 mg/l<25
Follicle-Stimulating Hormone (FSH)1.5-12.4 iu/l0.8
Luteinizing Hormone (LH)1.7-8.6 iu/l0.1
Testosterone (bounded)9.9-27.8 nmol/l0.77
Thyroid Stimulating Hormone (TSH)0.27-4.2 mIU/l<0.005
Free Thyroxine (fT4)12-22 pmol/l24.1
TSH Receptor Antibody (TRAb)<1.8 iu/l3.5
Thyroid Peroxidase antibody (Anti-TPO)5-34 iu/mL175
Prolactin86-324 mIU/l808
Table 2
Hormonal TestReference RangeResults
Feb 2018June 2018Oct 2018
8am Cortisol404404
Adrenocorticotrophic Hormone (ACTH)1.6-13.9pmol/l2.24.5
Random Growth Hormone (GH)<3.0 mg/l0.07<0.05
Insulin-like Growth Factor 1 (IGF-1)48-209 mg/l<25133
Follicle-Stimulating Hormone (FSH)1.5-12.4 iu/l0.80.8
Luteinizing Hormone (LH)1.7-8.6 iu/l0.10.1
Testosterone (bounded)9.9-27.8 nmol/l0.770.34
Thyroid Stimulating Hormone (TSH)0.27-4.2 mIU/l<0.0050.1602.61 [0.45-4.5]
Free Thyroxine (fT4)12-22 pmol/l24.1*10.2*5* [8-16]
TSH Receptor Antibody (TRAb)<1.8 iu/l3.5-
Thyroid Peroxidase antibody (Anti-TPO)5-34 iu/mL175-
Prolactin86-324 mIU/l808790

Learning points

• This is a rare case of concurrent Grave’s Disease and panhypopituitarism

• Interim treatment with carbimazole further confounded interpretation of the thyroid panel trend

• Long term treatment is unpredictable and will require close monitoring

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts